Dianthus Therapeutics (DNTH) Equity Ratio (2017 - 2025)
Historic Equity Ratio for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to 0.95.
- Dianthus Therapeutics' Equity Ratio fell 78.79% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year decrease of 78.79%. This contributed to the annual value of 0.94 for FY2024, which is 12.26% up from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' Equity Ratio is 0.95, which was down 78.79% from 0.93 recorded in Q2 2025.
- Dianthus Therapeutics' Equity Ratio's 5-year high stood at 0.97 during Q1 2024, with a 5-year trough of 0.78 in Q2 2023.
- Its 4-year average for Equity Ratio is 0.53, with a median of 0.93 in 2025.
- Data for Dianthus Therapeutics' Equity Ratio shows a peak YoY increase of 53769.16% (in 2023) and a maximum YoY decrease of 20087.62% (in 2023) over the last 5 years.
- Dianthus Therapeutics' Equity Ratio (Quarter) stood at 0.53 in 2022, then soared by 276.32% to 0.94 in 2023, then increased by 0.12% to 0.94 in 2024, then increased by 0.41% to 0.95 in 2025.
- Its Equity Ratio stands at 0.95 for Q3 2025, versus 0.93 for Q2 2025 and 0.94 for Q1 2025.